Affordable Access

Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma.

Authors
  • O'Connor, Owen A1
  • Hamlin, Paul A
  • Portlock, Carol
  • Moskowitz, Craig H
  • Noy, Ariela
  • Straus, David J
  • Macgregor-Cortelli, Barbara
  • Neylon, Ellen
  • Sarasohn, Debra
  • Dumetrescu, Otila
  • Mould, Diane R
  • Fleischer, Martin
  • Zelenetz, Andrew D
  • Sirotnak, Frank
  • Horwitz, Steven
  • 1 Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10032, USA. [email protected]
Type
Published Article
Journal
British journal of haematology
Publication Date
Nov 01, 2007
Volume
139
Issue
3
Pages
425–428
Identifiers
PMID: 17910632
Source
Medline
License
Unknown

Abstract

T-cell lymphomas (TCLs) are characterised by poor responses to therapy with brief durations of remissions. An early phase study of pralatrexate has demonstrated dramatic activity in patients with relapsed/refractory disease. Of the first 20 lymphoma patients treated, 16 had B-cell lymphoma and four had refractory aggressive TCL. All four patients with TCL achieved a complete remission. Patients with B-cell lymphoma achieved stable disease at best. For each TCL patient, the response was more durable than their best response with chemotherapy. This early experience is the first to document this unique activity of pralatrexate in TCL.

Report this publication

Statistics

Seen <100 times